Drugs / ABBV-184
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04272203 | May 2020 → Jun 2022 | acute myeloid leukemia, non-small cell lung carcinoma | AbbVie | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04272203 ↗ |
| Modality | Protein / enzyme biologic | “ABBV-184, a novel survivin peptide-targeting T-cell receptor (TCR)/anti-CD3 bispecific protein” PMID 38946484 ↗ Jul 2024 |
| Route | Intravenous | “Participants will receive weight based intravenous (IV) infusion of ABBV-184 once a week.” NCT04272203 ↗ |